These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 6851578)
1. Rejoinder: statistical inference from trials with sequential stopping rules. Dupont WD Control Clin Trials; 1983 Mar; 4(1):27-33. PubMed ID: 6851578 [No Abstract] [Full Text] [Related]
2. Current research in statistical methodology for clinical trials. Meier P Biometrics; 1982 Mar; 38 Suppl():141-53. PubMed ID: 7046819 [TBL] [Abstract][Full Text] [Related]
3. On the frequentist and likelihood controversy over sequential stopping rules in clinical trials. Herson J Control Clin Trials; 1983 Sep; 4(3):261-3. PubMed ID: 6641238 [No Abstract] [Full Text] [Related]
4. Discussion on early stopping. Greenhouse SW Control Clin Trials; 1983 Mar; 4(1):19-21. PubMed ID: 6851577 [No Abstract] [Full Text] [Related]
5. Comments on Dupont's article on sequential stopping rules. Whitehead J Control Clin Trials; 1983 Sep; 4(3):259-60. PubMed ID: 6641237 [No Abstract] [Full Text] [Related]
6. Sequential clinical trials in cancer research. George SL Cancer Treat Rep; 1980; 64(2-3):393-7. PubMed ID: 7407775 [TBL] [Abstract][Full Text] [Related]
7. Sequential stopping rules in clinical trials. McPherson K Stat Med; 1990 Jun; 9(6):595-600. PubMed ID: 2218163 [TBL] [Abstract][Full Text] [Related]
8. The impact that group sequential tests would have made on ECOG clinical trials. Rosner GL; Tsiatis AA Stat Med; 1989 Apr; 8(4):505-16. PubMed ID: 2657957 [TBL] [Abstract][Full Text] [Related]
9. Sequential clinical trials for normal variates using interval composite hypotheses. Lachin JM Biometrics; 1981 Mar; 37(1):87-101. PubMed ID: 7248445 [TBL] [Abstract][Full Text] [Related]
10. Assessment of futility in clinical trials. Snapinn S; Chen MG; Jiang Q; Koutsoukos T Pharm Stat; 2006; 5(4):273-81. PubMed ID: 17128426 [TBL] [Abstract][Full Text] [Related]
11. Ethics and statistical methodology in clinical trials. Palmer CR J Med Ethics; 1993 Dec; 19(4):219-22. PubMed ID: 8308877 [TBL] [Abstract][Full Text] [Related]
12. Early stopping of clinical trials in lupus and other uncommon rheumatologic diseases. LaValley MP; Felson DT Lupus; 1999; 8(8):698-703. PubMed ID: 10568909 [TBL] [Abstract][Full Text] [Related]
13. Further comment on "Statistical inference from clinical trials: choosing the right P value". Canner PL Control Clin Trials; 1983 Mar; 4(1):35. PubMed ID: 6851580 [No Abstract] [Full Text] [Related]
14. Comment on "Statistical inference from clinical trials: choosing the right P value". Canner PL Control Clin Trials; 1983 Mar; 4(1):13-7. PubMed ID: 6851576 [No Abstract] [Full Text] [Related]
15. Too good to be true? Aspirin and schizophrenia. Shader RI J Clin Psychopharmacol; 2012 Oct; 32(5):583-4. PubMed ID: 22926589 [No Abstract] [Full Text] [Related]
16. Stopping rules for clinical trials. Freedman LS; Lowe D; Macaskill P Stat Med; 1983; 2(2):167-74. PubMed ID: 6648131 [TBL] [Abstract][Full Text] [Related]
17. Group sequential methods for cluster randomization trials with binary outcomes. Zou GY; Donner A; Klar N Clin Trials; 2005; 2(6):479-87. PubMed ID: 16422308 [TBL] [Abstract][Full Text] [Related]
18. Issues in the use of adaptive clinical trial designs. Emerson SS Stat Med; 2006 Oct; 25(19):3270-96; discussion 3302-4, 3320-5, 3326-47. PubMed ID: 16906553 [TBL] [Abstract][Full Text] [Related]